Rarer changes

Rarer changes: BRAF, MET, RET, NTRK, HER2

Does your report show a rarer change? Each one is explained here in the same way: what it means, how common it is and which treatments are authorised in the EU.

  • 4 min read
  • Updated 17 November 2026

Most important in brief

  • Each rare change affects 1 to 3 in 100 people with NSCLC, but together they affect many.
  • For BRAF V600E or RET, tablets are available as the first treatment.
  • For MET exon 14, HER2 or NTRK, targeted medicines in the EU usually come after a first treatment.
  • For KRAS forms other than G12C, there is no authorised tablet yet.
  • Ask for the exact name of your change. It decides the treatment.

Why this page

Today, lung cancer is told apart by changes in the tumour. Many of them are rare. Rare does not mean unimportant: for most of them, a medicine is now authorised.

Changes found in about 4 in 100 people with NSCLC or more have their own page: EGFR, KRAS G12C, ALK. ROS1 shares the ALK page. All others are explained here, each in the same way.

The rarer changes at a glance

ChangeFirst treatmentLater
BRAF V600E
Two tablets together (BRAF and MEK inhibitors).e.g.+or+
Immunotherapy or chemotherapy, if not given yet.
MET exon 14
Usually immunotherapy, often with chemotherapy.
MET tablet, after immunotherapy or platinum chemotherapy.e.g.or
RET
RET tablet.e.g.
Immunotherapy or chemotherapy, if not given yet.
NTRK
Usually the standard treatment first.
NTRK tablet, when other treatments are not suitable.e.g.or
HER2
Usually immunotherapy, often with chemotherapy.
Antibody-drug conjugate by infusion, after platinum chemotherapy.e.g.
Other KRAS forms
Usually immunotherapy, often with chemotherapy.
Chemotherapy. New medicines against these forms are being tested in trials.

Simplified, as of November 2026, based on ESMO, Onkopedia and the EU authorisations. Examples without ranking. What is available and paid for differs by country.

Each change in turn

BRAF V600E in lung cancer

Mutationin about 1 to 2 in 100 people with NSCLC

A gene in the growth pathway that is permanently active. Two tablets together, often as the first treatment.

First treatment
Two tablets together (BRAF and MEK inhibitors).e.g.+or+
Later
Immunotherapy or chemotherapy, if not given yet.

EU authorisation: EMA dabrafenib, EMA trametinib, EMA encorafenib, EMA binimetinib

MET exon 14 in lung cancer

Change (exon 14 skipping)in about 3 in 100 people with NSCLC

Part of the MET gene is skipped and the signal stays on. More common in older people. Targeted tablets, in the EU after a first treatment.

First treatment
Usually immunotherapy, often with chemotherapy.
Later
MET tablet, after immunotherapy or platinum chemotherapy.e.g.or

EU authorisation: EMA capmatinib, EMA tepotinib

RET in lung cancer

Gene fusionin about 1 to 2 in 100 people with NSCLC

A gene fusion, similar to ALK. More common in people who never smoked. Targeted tablet, often as the first treatment.

First treatment
RET tablet.e.g.
Later
Immunotherapy or chemotherapy, if not given yet.

EU authorisation: EMA selpercatinib

NTRK in lung cancer

Gene fusionin fewer than 1 in 100 people with NSCLC

A very rare gene fusion that occurs in many types of cancer. Tablets authorised for any cancer with this fusion.

First treatment
Usually the standard treatment first.
Later
NTRK tablet, when other treatments are not suitable.e.g.or

EU authorisation: EMA larotrectinib, EMA entrectinib

HER2 in lung cancer

Mutationin about 2 to 3 in 100 people with NSCLC

A mutation in the HER2 gene. Not the same as “HER2-positive” in breast cancer. An antibody medicine, in the EU after a first treatment.

First treatment
Usually immunotherapy, often with chemotherapy.
Later
Antibody-drug conjugate by infusion, after platinum chemotherapy.e.g.

EU authorisation: EMA trastuzumab deruxtecan

Other KRAS forms in lung cancer

Mutation

For example G12D, G12V or G13. Common, but different from G12C. No authorised tablet yet. Treated as if no change was found.

First treatment
Usually immunotherapy, often with chemotherapy.
Later
Chemotherapy. New medicines against these forms are being tested in trials.

Questions for a rare change

  • Why ask?

    Only the exact name leads to the matching medicine.

  • Why ask?

    Some medicines come as the first treatment, some later.

  • Why ask?

    Rare medicines are often not on the list; sometimes there are other ways, such as a study.

  • Why ask?

    For rare changes, studies are often an important way to reach new medicines.

Sources

  1. ESMO Living Guideline: oncogene-addicted metastatic NSCLC
  2. Onkopedia: Lungenkarzinom, nicht-kleinzellig (NSCLC)
  3. EMA: EPAR dabrafenib
  4. EMA: EPAR trametinib
  5. EMA: EPAR encorafenib
  6. EMA: EPAR binimetinib
  7. EMA: EPAR capmatinib
  8. EMA: EPAR tepotinib
  9. EMA: EPAR selpercatinib
  10. EMA: EPAR larotrectinib
  11. EMA: EPAR entrectinib
  12. EMA: EPAR trastuzumab deruxtecan

All sources last checked on 12 November 2026, unless another date is given.